Literature DB >> 29876314

Proton therapy for thoracic reirradiation of non-small cell lung cancer.

Hann-Hsiang Chao1, Abigail T Berman1.   

Abstract

Lung cancer is a leading cause of cancer death with frequent local failures after initial curative-intent treatment. Locally recurrent non-small cell lung cancer represents a challenging clinical scenario as patients have often received prior radiation as part of a definitive treatment regimen. Proton beam therapy, through its characteristic Bragg peak and lack of exit dose is a potential means of minimizing the toxicity to previously irradiated organs and improving the therapeutic ratio. This article aims to review the rationale for the use of proton beam therapy for treatment of locally recurrent non-small cell lung cancer, highlight the current published experience on the feasibility, efficacy, and limitations of proton beam reirradiation, and discuss future avenues for improved patient selection and treatment delivery.

Entities:  

Keywords:  Proton beam therapy; intensity-modulated proton therapy (IMPT); non-small cell lung cancer (NSCLC); reirradiation

Year:  2018        PMID: 29876314      PMCID: PMC5960656          DOI: 10.21037/tlcr.2018.03.22

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  42 in total

1.  Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma.

Authors:  T Le Chevalier; R Arriagada; E Quoix; P Ruffie; M Martin; J Y Douillard; M Tarayre; M J Lacombe-Terrier; A Laplanche
Journal:  Lung Cancer       Date:  1994-03       Impact factor: 5.705

2.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors:  Marina Chiara Garassino; Olga Martelli; Massimo Broggini; Gabriella Farina; Silvio Veronese; Eliana Rulli; Filippo Bianchi; Anna Bettini; Flavia Longo; Luca Moscetti; Maurizio Tomirotti; Mirko Marabese; Monica Ganzinelli; Calogero Lauricella; Roberto Labianca; Irene Floriani; Giuseppe Giaccone; Valter Torri; Alberto Scanni; Silvia Marsoni
Journal:  Lancet Oncol       Date:  2013-07-22       Impact factor: 41.316

3.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

Review 4.  The use of proton therapy in the treatment of lung cancers.

Authors:  Charles B Simone; Ramesh Rengan
Journal:  Cancer J       Date:  2014 Nov-Dec       Impact factor: 3.360

5.  Reirradiation of thoracic cancers with intensity modulated proton therapy.

Authors:  Jennifer C Ho; Quynh-Nhu Nguyen; Heng Li; Pamela K Allen; Xiaodong Zhang; Zhongxing Liao; X Ronald Zhu; Daniel Gomez; Steven H Lin; Michael Gillin; Ritsuko Komaki; Stephen Hahn; Joe Y Chang
Journal:  Pract Radiat Oncol       Date:  2017-07-08

Review 6.  Systematic review: charged-particle radiation therapy for cancer.

Authors:  Teruhiko Terasawa; Tomas Dvorak; Stanley Ip; Gowri Raman; Joseph Lau; Thomas A Trikalinos
Journal:  Ann Intern Med       Date:  2009-09-14       Impact factor: 25.391

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

8.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

9.  Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis.

Authors:  O Kenneth Macdonald; Jon J Kruse; Janelle M Miller; Yolanda I Garces; Paul D Brown; Robert C Miller; Robert L Foote
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-01       Impact factor: 7.038

10.  An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer.

Authors:  Abigail T Berman; Boon-Keng Kevin Teo; Derek Dolney; Samuel Swisher-McClure; Kambiz Shahnazi; Stefan Both; Ramesh Rengan
Journal:  Radiat Oncol       Date:  2013-06-15       Impact factor: 3.481

View more
  1 in total

1.  Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer.

Authors:  Kyungmi Yang; Yang-Gun Suh; Hyunju Shin; Hongryull Pyo; Sung Ho Moon; Yong Chan Ahn; Dongryul Oh; Eunah Chung; Kwanghyun Jo; Jae Myoung Noh
Journal:  Life (Basel)       Date:  2022-02-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.